SCHEMBL570221

SCHEMBL570221

[c]1nccnc1-c1ccco1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 6/20 0.42
HSD17B10 Q99714 6/20 0.42
POLB P06746 4/20 0.42
PKM P14618 4/20 0.42
MAPT P10636 4/20 0.42
RAB9A P51151 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
NPC1 O15118 2/20 0.42
HPGD P15428 2/20 0.42
ALOX15 P16050 2/20 0.42
CASP1 P29466 2/20 0.42
PTPN7 P35236 2/20 0.42
RECQL P46063 2/20 0.42
BLM P54132 2/20 0.42
CASP7 P55210 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989146 0.73 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL450165 0.71 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL31064873 0.70 ALDH1A1 (0.65) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL17965523 0.68 HPGDS (0.38)
SCHEMBL559143 0.67 MTOR (0.39) ALDH1A1MEN1KMT2APKMRAB9A
SCHEMBL4587267 0.67 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL5259444 0.66 POLB (0.65) ALDH1A1MEN1KMT2AKDM4EHSD17B10
SCHEMBL584984 0.66 KDM4E (0.31) KDM4ETDP1TP53
SCHEMBL5503401 0.65 CYP1A2 (0.33) RAB9ANPC1CYP19A1
SCHEMBL1799678 0.65 ALDH1A1 (0.63) ALDH1A1MEN1KMT2AKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY NOVALIX DEUTSCHLAND GMBH (DE) 2017-06-01 US disclosed
US-8980322-B2 Controlled release composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-03-17 US disclosed
EP-2601208-B1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2015-02-11 EP disclosed
EP-1681290-B9 Imidazole derivatives, production method thereof and use thereof TAKEDA PHARMACEUTICAL (JP) 2013-06-19 EP disclosed
EP-2601208-A2 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY Graffinity Pharmaceuticals GmbH (DE) 2013-06-12 EP disclosed
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2013-05-23 US disclosed
WO-2012017021-A2 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY GRAFFINITY PHARMACEUTICALS GMBH (DE) 2012-02-09 WO disclosed
EP-1681290-B1 Imidazole derivatives, production method thereof and use thereof TAKEDA PHARMACEUTICAL (JP) 2011-11-16 EP disclosed
US-20110263595-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Opna Bio SA (CH) 2011-10-27 US disclosed
EP-1344777-B1 IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE TAKEDA PHARMACEUTICAL (JP) 2011-03-16 EP disclosed
EP-1681290-A2 Imidazole derivatives, production method thereof and use thereof Takeda Pharmaceutical Company Limited (JP) 2006-07-19 EP disclosed
EP-1607088-A1 CONTROLLED RELEASE COMPOSITION Takeda Pharmaceutical Company Limited (JP) 2005-12-21 EP disclosed
US-6960586-B2 Imidazole derivatives, process for their preparation and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-01 US disclosed
US-6713632-B1 Process for the preparation of imidazole derivatives TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-03-30 US disclosed
US-20040033935-A1 Novel imidazole derivatives, production method thereof and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-19 US disclosed
US-20040024039-A1 Imidazole derivatives, process for their preparation and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-02-05 US disclosed
EP-1344777-A1 IMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE Takeda Chemical Industries, Ltd. (JP) 2003-09-17 EP disclosed
EP-1334106-A2 NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-08-13 EP disclosed
WO-2002040484-A2 NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-05-23 WO disclosed
EP-1193258-A1 PROCESS FOR THE PREPARATION OF IMIDAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040033935-A1 Novel imidazole derivatives, production method thereof and use thereof CYP17A1, CYP21A2, CYP19A1 ALDH1A1 227/4885MEN1 2631/4885KMT2A 1405/4885
US-20170152288-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCGR3B ALDH1A1 4076/4885MEN1 3656/4885KMT2A 2553/4885
US-20110263595-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, NTRK1, PRKDC ALDH1A1 3884/4885MEN1 1106/4885KMT2A 2694/4885
US-20040024039-A1 Imidazole derivatives, process for their preparation and their use CYP17A1, HSD17B7, CYP51A1 ALDH1A1 164/4885MEN1 1659/4885KMT2A 1237/4885
US-20130131321-A1 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY FCGR1A, FCGR2A, FCER2 ALDH1A1 2263/4885MEN1 3015/4885KMT2A 1127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.